Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)

Fei Li, Shou-Ching Tang

Research output: Contribution to journalEditorial

7 Scopus citations


We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalGenes and Diseases
Issue number1
StatePublished - Mar 1 2017



  • ANG1005
  • Brain metastasis
  • Breast cancer
  • LRP-1
  • The blood-brain-barrier

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics(clinical)
  • Cell Biology

Cite this